RETAVASE® (reteplase) is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin degrades the fibrin matrix of the thrombus, exerting its thrombolytic action.

To reduce the risk of death and heart failure
in acute STEMI, RETAVASE
Helps break through clots with zero dose calculations

Full Prescribing Information

RETAVASE achieved greater than 80% rate of TIMI 2 or 3 flow at 90 minutes in patients with acute STEMI1‑3

In clinical trials, more patients achieved TIMI 3 flow at 90 minutes with RETAVASE 10 + 10 unit vs alteplase (100 mg over 1.5 hours or over 3 hours).1-3


The only fibrinolytic for acute STEMI with non–weight‑based dosing


Review the RETAVASE clinical efficacy results.

Higher rates of TIMI 2 or 3 flow vs alteplase

Review the clinical efficacy results.

Learn about the administration of RETAVASE.

Dosing & administration

Learn about the administration of RETAVASE.

Download order sheet and get storage and handling information.

Order RETAVASE

Download the order sheet and get storage and handling information.

Medical Information rep photo

Medical Information

Have questions? For additional assistance or questions not answered on this website, contact Chiesi USA, Inc.

Contact Us